...Scientists from Queen Mary University of London have found a new ther...The research published in the journal Cellular and Molecular Life ...Dr Martin Knight who led the research at Queen Mary's School of Engine...The researchers investigated the role of primary cilia in inflammation...

Scientists from Queen Mary, University of London have found a new therapeutic target to combat inflammation.

The research, published in the journal Cellular and Molecular Life Sciences, revealed tiny organelles called primary cilia are important for regulating inflammation. The findings could lead to potential therapies for millions of people who suffer from arthritis*.

Dr Martin Knight who led the research at Queen Mary's School of Engineering and Materials Science said: "Although primary cilia were discovered more than a century ago, we're only beginning to realise the importance they play in different diseases and conditions, and the potential therapeutic benefits that could be developed from manipulating cilia structure and function."

The researchers investigated the role of primary cilia in inflammation. They took cartilage cells and exposed them to a group of inflammatory proteins called cytokines, specifically interleukin-1 (IL-1), to see whether there were any changes to the primary cilia.

"When we exposed the cells to IL-1, in just three hours the primary cilia showed a 50 per cent increase in length," he said.

"But what was most interesting was when we treated cells to prevent this elongation of the cilium. The cartilage cells had a greatly reduced response to the inflammatory proteins and were therefore not as inflamed. This suggests a brand new therapeutic target for inflammation."

Co-author Dr Angus Wann, said this is the first time primary cilia have been suggested as a target for novel therapies to reduce the effects of inflammation.

"If we can work out how to better manipulate the primary cilium, we could potentially attenuate or even prevent inflammation," he said.

(Date:12/7/2016)... Avanade is helping Williams Martini Racing, one of ... biometric data in order to critically analyse every aspect ... against their rivals after their impressive, record-breaking pit stop ... with Williams during the 2016 season to capture and ... rate, temperature and peak acceleration) for key members of ...

(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...

(Date:12/7/2016)... the association for the California life ... st Century Cures legislation in Congress. The bill passed ... and in the Senate on December 7 by a 94-5 ... , president & CEO of Biocom: "Today, Congress ... patients around the world. The measure culminates three years of ...

(Date:12/7/2016)... -- Vyriad Inc. announced today the appointment of Alvin ... "We are delighted to welcome Al to ... our oncolytic viruses as the next generation of precision ... MD, PhD, CEO of Vyriad. "Al and his wife, ... for making a difference for cancer patients—their philanthropy has ...

(Date:12/7/2016)... Muse bio, a privately-held company leading the development ... Kevin Ness has been appointed Chief Executive ... Kevin succeeds Muse bio,s founding CEO ... Officer as well as remains Slade Professor, Chemical and ... at the RAS Energy Institute at the University of ...